ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1158

Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis

Spondyloarthritis Including PsA – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1153

Differentially Expressed Genes in Males and Females with Ankylosing Spondylitis (AS): Transcriptomics of IL-17-producing Cells in Patients with AS

Spondyloarthritis Including PsA – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1487

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1364

Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the the Juvenile Scleroderma Inception Cohort

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1565

Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1556

Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1171

Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease

Systemic Sclerosis and Related Disorders – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1390

Distinct Patterns of Multimorbidity Are Associated with Longitudinal Disease Activity and Functional Status in a Multicenter, Prospective Rheumatoid Arthritis Cohort

RA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1228

Distinctive Alterations in the Functional Anatomy of the Cerebral Cortex in Pain-sensitized Osteoarthritis and Fibromyalgia Patients

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1496

Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1264

Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1169

Downregulated Fli1 in Systemic Sclerosis Myeloid Cells Contributes to Enhanced Transendothelial Migration

Systemic Sclerosis and Related Disorders – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1195

Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1413

Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study

RA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1354

Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application

Patient Outcomes, Preferences, and Attitudes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].